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ABSTRACT Metallo--lactamases (MBLs) threaten the effectiveness of -lactam anti-
biotics, including carbapenems, and are a concern for global public health. -
Lactam/-lactamase inhibitor combinations active against class A and class D car-
bapenemases are used, but no clinically useful MBL inhibitor is currently available.
Tripoli metallo--lactamase-1 (TMB-1) and TMB-2 are members of MBL subclass B1a,
where TMB-2 is an S228P variant of TMB-1. The role of S228P was studied by com-
parisons of TMB-1 and TMB-2, and E119 was investigated through the construction
of site-directed mutants of TMB-1, E119Q, E119S, and E119A (E119Q/S/A). All TMB
variants were characterized through enzyme kinetic studies. Thermostability and
crystallization analyses of TMB-1 were performed. Thiol-based inhibitors were investi-
gated by determining the 50% inhibitory concentrations (IC50) and binding using
surface plasmon resonance (SPR) for analysis of TMB-1. Thermostability measure-
ments found TMB-1 to be stabilized by high NaCl concentrations. Steady-state en-
zyme kinetics analyses found substitutions of E119, in particular, substitutions associ-
ated with the penicillins, to affect hydrolysis to some extent. TMB-2 with S228P
showed slightly reduced catalytic efficiency compared to TMB-1. The IC50 levels of
the new thiol-based inhibitors were 0.66 M (inhibitor 2a) and 0.62 M (inhibitor
2b), and the equilibrium dissociation constant (KD) of inhibitor 2a was 1.6 M; thus,
both were more potent inhibitors than L-captopril (IC50  47 M; KD  25 M). The
crystal structure of TMB-1 was resolved to 1.75 Å. Modeling of inhibitor 2b in the
TMB-1 active site suggested that the presence of the W64 residue results in
T-shaped - stacking and R224 cation- interactions with the phenyl ring of the
inhibitor. In sum, the results suggest that residues 119 and 228 affect the catalytic
efficiency of TMB-1 and that inhibitors 2a and 2b are more potent inhibitors for
TMB-1 than L-captopril.
KEYWORDS metallo--lactamase, TMB-1, TMB-2, thermal stability, enzyme kinetics,
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Carbapenems are considered the “last resort” therapy for treating serious bacterialinfections (1). The dominant mechanisms of resistance against carbapenems are
-lactamase enzymes with activity against carbapenems (also called carbapen-
emases) (2). Carbapenemases have been identified among Ambler class A, B, and D
-lactamases. Class B represents the metallo--lactamases (MBLs), which contain one or
two zinc ions in the active site essential for the enzymatic activity (3). MBLs are divided
into four subclasses, according to their primary structural and molecular characteristics:
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B1a (e.g., VIM, IMP, DIM, and GIM), B1b (NDM), B2 (e.g., CphA), and B3 (e.g., L1 and AIM)
(4). MBLs have been found in many clinically relevant Gram-negative bacterial species
such as Pseudomonas aeruginosa, Acinetobacter baumannii, and different Enterobacte-
riaceae. The dissemination of carbapenemases is a major public health problem, and there
has been no effective MBL inhibitor available to date that could restore the effect of
-lactams when coadministered. Fragment-based library screening has shown that frag-
ments containing a thiol group are able to inhibit MBLs (5). Thiol fragments are thought to
inhibit MBLs through bridging the two zinc ions in the active site, by replacing the bridging
hydroxyl ion (6). Studies of different thiol-containing compounds (6–11) have shown
inhibitory effects on many MBLs. For instance, captopril, which has a thiol group and is used
as an angiotensin converting enzyme (ACE) inhibitor for treating hypertension, shows an
inhibitory effect on MBLs (12, 13).
The Tripoli metallo--lactamase-1 (TMB-1) gene was first discovered in a Achromo-
bacter xylosoxidans strain obtained from an environmental sample in a hospital in
Tripoli, Libya, in 2011 (14). TMB-1 belongs to subclass B1a and is most closely related
to DIM-1 (62%) and GIM-1 (51%) at the amino acid sequence level and shows more
limited similarity to IMP-1 (48%), VIM-2 (31%), and NDM-1 (29%) (14). After the initial
report, TMB-1 has been identified in clinical isolates of Acinetobacter spp. in Japan (15),
and the new TMB-1 variant named TMB-2, with the single mutation S228P, was isolated
from a different hospital in Japan also in clinical isolates of Acinetobacter spp. (16).
The B1 MBLs contain a conserved H116XH118XD120 motif (according to the standard
numbering scheme for class B -lactamases [17, 61]) that is involved in binding of both
Zn1 and Zn2 in the active site. In TMB-1, serine (S) and glutamic acid (E) are located at
positions 117 and 119, respectively, similarly to other MBLs, e.g., GIM-1 (18). IMP-1 and
NDM-1 have serine and glutamine (Q), respectively, at position 119 (14). Studies on the
effect of substitutions of second-shell-sphere residue 119 are limited. However, the
residue is thought to affect the substrate specificity. Mutational studies of residue 119
have to our knowledge been reported in NDM-1 only, where glutamine was mutated
to aspartic acid (D), serine, and alanine (A) (19). The MIC for NDM-1 Q119D/S/A mutants
were reduced for ampicillin, meropenem, and cefepime substrates, while mutant
NDM-1 Q119D showed reduced drug MIC with all substrates tested compared to
NDM-1. The NDM-1 Q119D mutant showed lower levels of catalytic efficiency toward
ampicillin, meropenem, ertapenem, and cefepime substrates tested in the enzyme
kinetic assay than seen with NDM-1 (19). Further, residue 119 has been reported to be
involved in binding of inhibitors in IMP-1, BlaB, and CphA (5, 7, 20, 21), biapenem in
CphA (22) and penicillin substrates in NDM-1 (23, 24). The effect of substitutions of E119
in TMB-1 was studied here.
TMB-2 differs from TMB-1 by only the presence of a proline (P) at position 228
instead of a serine. Previous studies found that substitutions of residue 228 affected
catalytic efficiency in, e.g., GIM-1 (25). Residue 228 has been thoroughly studied in
several MBL enzymes; however, a proline variant similar to that found in TMB-2 has
been described only in a VIM-2 R228P mutant (11). Residue 228 is located in MBL loop
L3 (residues 223 to 240) and has been reported to contribute to substrate specificity
(25, 26) and to be involved in inhibitor binding (8, 27).
In this study, the effects of residue 119 in the TMB-1 mutants E119Q, E119S, and
E119A (E119Q/S/A) and of proline at position 228 (as in TMB-2) on the hydrolysis of a
range of substrates were investigated. Mutations at position 119 were based mainly on
residues found in other MBLs. Glutamic acid (E) was mutated to glutamine (Q), as
in NDM-1, and to serine (S), as in IMP-1. The alanine (A) mutation was included to
investigate the effect of a smaller residue at position 119. The structure of TMB-1 was
solved by X-ray crystallography, and an inhibitor was modeled into the TMB-1 active
site to investigate the possible modes of inhibitor binding in TMB-1. The results show
that the introduction of E119Q/S/A in TMB-1 or of a S228P mutation in TMB-2 gives, in
general, a reduced level of catalytic efficiency compared to TMB-1, meaning that
residues 119 and 228 are important for the substrate specificity of TMB-1. The inhibitor
testing shows promising results for further inhibitor optimization.
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Buffer optimization using thermofluor stability measurement. TMB-1, TMB-2,
and the three TMB-1 mutants were expressed and purified; however, shortly after
purification, the enzymes precipitated. In order to investigate buffer components with
a stabilizing effect on the enzyme and to prevent precipitation, a thermofluor-based
thermostability buffer was used and additive screening was performed for TMB-1 (see
Table S1 in the supplemental material). The measurements revealed that increasing the
NaCl concentration to 1.0 M gave a stabilization effect with a 2.4°C-higher melting
temperature (Tm) for TMB-1 (see Fig. S1 in supplemental material). Consequently, 1.0 M
NaCl was included in the resuspension, purification, and storage buffers. The solubility
and long-term storage of TMB-1 and TMB-2 and all of the TMB-1 mutants (E119Q/S/A)
were improved. The reason for the improved stability at high levels of salt could be that
the TMB-1 sequence was more polar (lower hydropathicity index; Table S2) than the
more neutral VIM-1 and NDM-1 sequences. The levels of purity of TMB-1, TMB-2, and
the E119Q/S/A TMB-1 mutants were estimated to be 95% (Fig. S2), and the identities
of TMB-1 and TMB-2 were confirmed by tandem mass spectrometry (MS/MS) analysis
(data not shown).
Enzymatic kinetic characterization of TMB-1. The hydrolytic spectrum recorded
for TMB-1 (Table 1) shows that the catalytic efficiency toward -lactam substrates
without a positively charged R2 group (cefoxitin, cefotaxime, meropenem, doripenem)
was more efficient than for the substrates within the respective -lactam groups
containing a positively charged R2 group (cefepime, ceftazidime, and imipenem). The
levels of catalytic efficiency (kcat/Km) of TMB-1 against carbapenem substrates mero-
penem and doripenem were 2 and 23 times higher than against the positively charged
imipenem, respectively. For the cephalosporin group, the levels of catalytic efficiency of
cefotaxime and cefoxitin were 3.8 and 4.4 times higher than that of ceftazidime,
respectively, and 114 and 100 times higher than that of cefepime, respectively. This
might have been due to the presence of the positively charged R224 in the R2 binding
site of TMB-1. Most MBLs contain a positively charged K224 residue, shown to be
involved in substrate binding in NDM-1 (23, 24, 28) and in inhibitor binding in NDM-1
(29) and IMP-1 (6, 30, 31). The TMB-1 hydrolysis of ampicillin, benzylpenicillin, and
piperacillin substrates resulted in activity within the same range, from 0.8 to 1.3 s1
M1. The turnover number (kcat) of ampicillin in TMB-1 is slightly better than that seen
with benzylpenicillin and piperacillin, possibly due to the presence of an amine in the
R1 part of ampicillin.
The hydrolytic spectrum of TMB-1 compared to those of VIM-2 (32, 33), NDM-1 (19,
34), and GIM-1 (25, 35) reveals that, in general, the catalytic efficiency for TMB-1 is lower
than for VIM-2 and NDM-1, while TMB-1 shows activity similar to or somewhat higher
than that of GIM-1 against the tested substrates. VIM-2 and NDM-1 hydrolyze carbap-
enem substrates more efficiently than TMB-1 and GIM-1; VIM-2 also shows higher
catalytic efficiency toward cephalosporins than TMB-1, while TMB-1 has slightly higher
activity toward cephalosporins than NDM-1. The activity of VIM-2 against benzylpeni-
cillin is four times higher than that of TMB-1, while the catalytic efficiency of NDM-1
toward ampicillin is two times higher than that for TMB-1. The reduced activity of both
TMB-1 and GIM-1 may be attributable to the presence of the tyrosine at position 233,
which cannot form the interaction to substrates seen in NDM-1 MBL containing an
asparagine (N) at this position. The asparagines at the 233 position, present in most
MBLs, are interacting through the amine side chain with the substrate carboxyl group
(28).
The role of residue 228 in enzymatic activity. Kinetic analyses of TMB-1 and TMB-2
were conducted in order to characterize the influence of the proline residue at position 228
in TMB-2 on its enzymatic properties (Table 1).
The kinetics data of TMB-2 and TMB-1 (Table 1) show a slight reduction in catalytic
efficiency for TMB-2 toward all substrates used in this study and reduced activity with
ampicillin as the substrate due to binding that was 3.7 times weaker. For TMB-2, tighter
Effects from Changing Residue 119 or 228 in TMB-1 Antimicrobial Agents and Chemotherapy
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binding to all carbapenem and cephalosporin substrates and to most penicillin sub-
strates was observed; however, the low turnover numbers resulted in reduced catalytic
efficiency compared to that seen with TMB-1. Ampicillin and benzylpenicillin showed
slightly weaker binding to TMB-2 than to TMB-1. Both substrates have a small R1 group
compared to piperacillin. Residue 228 has not been shown to be involved in the
binding of penicillin substrates with small R2 groups; however, the residue seems to
affect neighboring residues in the active site, including the L3 loop, which again affects
the binding of penicillin substrates. Residue 228 is located adjacent to the active-site
Zn2 in the so-called R2 binding site (36) and is a part of the MBL L3 loop. Substitutions
at position 228 have been shown to be tolerated for different substrates (37) but have
also been found to affect the substrate specificity of, e.g., GIM-1 (25). S228 in VIM-26
was reported to contribute to formation of a larger active-site pocket, leaving more
space for substrates with larger R2 groups compared to, e.g., VIM-2 and VIM-7 with an
arginine residue at this position (38). For TMB-2, the substitution of a proline at position
228 gives conformational rigidity in the L3 loop; the loop is expected to become less
flexible, and this might explain the observed small reduction in the catalytic efficiency
of TMB-2.
Taking the data together, the introduction of a rigid proline residue at position 228
in TMB-2 does not have a significant effect on the activity; however, there is a slight
reduction in catalytic efficiency compared to TMB-1.
Effect on the enzymatic properties for the TMB-1 E119Q/S/A mutants. Our
TMB-1 data show that, in general, TMB-1 has higher catalytic efficiency than the TMB-1
E119Q/S/A mutants (Table 1). The substitutions to E119Q/S/A at position 119 for TMB-1
show the most profound effect in reduced catalytic efficiency (kcat/Km) for penicillin
substrates, due to both weaker binding and lower turnover of penicillin substrates, for
almost all TMB-1 mutants compared to TMB-1. The effect of the TMB-1 substitutions on
the catalytic activity shows that residue 119 is contributing in binding penicillin
substrates. This conclusion is in agreement with reports of crystal structure complexes
of NDM-1 where residue Q119 is involved in hydrogen binding to the penicillin
substrate ampicillin (23, 24). The data indicating that the TMB-1 E119Q mutant showed
a reduced catalytic effect compared to wild-type TMB-1 are in contrast to the reported
results for NDM-1, where NDM-1 (with Q119) had higher catalytic efficiency than NDM-1
Q119D (19). For TMB-1, the presence of a long-chained negatively charged glutamic
acid at position 119 seems to increase the activity. However, the amino acid sequence
identity between TMB-1 and NDM-1 is only 29%; thus, other residues nearby might
contribute to this difference.
Additional residues involved in binding of ampicillin and benzylpenicillin in NDM-1
are K224 and N233 (23, 24). TMB-1 has an arginine at the 224 position and a tyrosine
at the 233 position. Substitution of K224 with an arginine has been studied in NDM-1,
with results showing no effect on the drug MIC for the NDM-1 K224R mutant, and the
product was suggested to be able to retain the hydrogen bond to the ampicillin and
other substrates (19). This supports the idea that R224 in TMB-1 contributes to the
substrate binding. Substitution of Y233 to asparagine has been investigated in GIM-1,
which shares 51% sequence identity with TMB-1. Here, the kinetic parameters revealed
that binding of ampicillin to GIM-1 Y233N was better than that to GIM-1 Y233; however,
the turnover number was lower, resulting in lower catalytic efficiency for the GIM-1
Y233N mutant (25).
Our TMB-1 kinetic studies found the binding affinity for TMB-1 E119Q toward
meropenem to be about 2-fold better (lower Km) than that for TMB-1. However, due to
the low turnover (kcat) for the TMB-1 E119Q mutant, the levels of catalytic efficiency
were similar. Generally, TMB-1 E119Q showed the best binding to carbapenem sub-
strates. The exception was TMB-1 E119S, which bound imipenem strongly at a level
similar to that seen with TMB-1 E119Q, but the reaction rate was lower, resulting in
activity in the same range as that seen with TMB-1. In crystal structures of NDM-1 with
hydrolyzed meropenem (Protein Data Bank [PDB] ID 4EYL), residue Q119 (named Q123
Effects from Changing Residue 119 or 228 in TMB-1 Antimicrobial Agents and Chemotherapy
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in the structure) makes a water-mediated hydrogen bond to the R1 hydroxymethyl
group in meropenem (24). A similar H-bonding pattern may explain the increased
binding affinity for carbapenems in TMB-1 E119Q.
Overall, the levels of catalytic efficiency of TMB-2 and TMB-1 E119Q/S/A mutants are
slightly reduced compared to those seen with TMB-1, with some exceptions. The E119
and S228 residues are second-shell binding residues supporting the active site and are
used to facilitate binding of -lactam substrates. Position 119 has shown to be essential
for hydrolysis of penicillin substrates but not of the other substrates.
Determination of the inhibitory activity of new thiol-based compounds. Thiol-
based inhibitors have previously been tested for their inhibition potential against the
MBLs VIM-2 and NDM-1 (8–10, 39) and have been shown in several studies to be good
MBL inhibitors (see, e.g., references 7 and 31). In this study, eight new thiol-based
inhibitors synthetized by us (40) were included and compared to L-captopril. The
binding affinity (Km) value for nitrocefin in TMB-1 was determined to be 25 M
compared to 34 M for VIM-2, 37 M for GIM-1, and 5 M for NDM-1 (data not shown)
and thus was determined to be a suitable reporter substrate for TMB-1.
Our new thiol-based inhibitors showed half-maximal (i.e., 50%) inhibitory concen-
tration (IC50) values ranging from 0.6 to 22.8 M toward TMB-1 (Table 2; see also Fig.
S3). Inhibitors 2a and 2b showed IC50 values as low as 0.66 and 0.62 M. The presence
of a thiol group in combination with the diethyl phosphonate esters as described for
inhibitors 2a and 2b resulted in inhibition properties better than those seen with
corresponding mercapto- and thioacetate phosphonic acids 3a to 3c and 10a to 10c,
respectively. This may indicate that the diethyl groups on the phosphonate esters (2a
and 2b) are important for inhibitory efficiency. The difference in chain length be-
tween inhibitor 2a and 2b (n  2 or 3; Table 2) did not change the inhibition potential,
considering the low IC50 values for both inhibitors.
Binding studies using SPR analysis with L-captopril and inhibitors 2a and 2b. A
surface plasmon resonance (SPR)-based biosensor assay was used to determine the
binding affinity (quantified as the equilibrium dissociation constant [KD]) of the two
best inhibitors for TMB-1. Different methods were used to immobilize TMB-1. Standard
amine coupling and streptavidin-biotin capturing showed similar results, and both
were used in the study. TMB-1 was immobilized on the SPR sensor surface, resulting in
an immobilization level of around 1,200 response units (RU).
In order to ensure that the immobilized TMB-1 protein was active on the surface,
interaction with meropenem and L-captopril was investigated. To study the interac-
tions, 2-fold concentrations series of meropenem and L-captopril were injected over the
surface. Although the signal intensity was low, a clear interaction with TMB-1 was
observed (Fig. 1 and 2). Due to the rapid interactions, the rate constants were


















































IC50 (μM) 47.1 0.66 0.62 15.1 22.8 18.3 10.4 17.5 14.6 
















1 Starng concentraon at 250 μM, whereas other inhibitors started at 2.5 mM. 
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impossible to determine. However, steady-state plots were used to calculate the
binding affinity (KD) value of meropenem of 19 M, which is in a range similar to
that of the Km of 36 M (Table 1) found in the steady-state kinetic measurements.
The calculated binding affinity (KD) of L-captopril was 14 M, which was in agree-
ment with the determined IC50 of 47.1 M (Fig. 2; Table 2). The inhibition of TMB-1
with L-captopril is similar that seen with BcII and IMP-1, with IC50 values of 80 M
and 23 M, respectively, while L-captopril was a better inhibitor for VIM-2 at
4 M and a poorer inhibitor for NDM-1 at 160 M (30). The interactions with
L-captopril and meropenem showed that TMB-1 was functionally active after im-
mobilization to the sensor surface and that the SPR assay was suitable for study of
the interaction with small compounds.
Compound 2a showed a well-defined interaction with TMB-1, with clear associ-
ation and dissociation phases (Fig. 2F). The sensorgrams were fitted to a 1:1
interaction model; the association constant (ka) was 3.4  103 M1 s1, and the
dissociation constant (Kd) was 0.0054 s1. The KD was calculated to be 1.6 M,
showing that compound 2a is a more potent inhibitor for TMB-1 than L-captopril
(with a KD of 14 M).
Also, compound 2b was analyzed in a 2-fold concentration series. The obtained
sensorgrams showed that compound 2b was binding to TMB-1; however, the data
quality was not sufficient to determine the KD. A possible explanation may be the
racemic 50:50 mixture of the enantiomers of the inhibitor. By separating the two
enantiomers, the use of the more efficient enantiomer may increase the data quality
and may in addition result in better binding affinity data for both the IC50 and SPR
measurements. This idea is supported by the data determined for the 1.55-Å structure
of VIM-2_2b, where only the (R)-enantiomer fits in the observed election density maps;
thus, the enzyme had been selective (40).
Crystal structure of TMB-1. In order to get information concerning the structure-
activity relationship of TMB-1, the crystal structure of the recombinant TMB-1 was
solved. High-quality diffraction crystals were obtained only after buffer optimization
and buffer exchange into 1.0 M NaCl in addition to 50 mM HEPES (pH 7.2) and 100 M
ZnSO4. The TMB-1 crystal structure was solved using molecular replacement, and a
homology model was solved with the TMB-1 sequence and the DIM-1 crystal structure
(PDB ID 4ZEJ). The TMB-1 crystals belong in space group P21212, with two molecules in
the asymmetric unit. The structure was resolved to 1.75 Å, and the final TMB-1 model
was refined to an R-factor value of 18.9% and an R-free value of 24.9%. The mean B
value was significantly lower for chain A (21.9 Å2) than for chain B (32.2 Å2), meaning
that the latter corresponded to a greater number of disordered residues, which does
not resemble the low Wilson B-factor value of 17.1 Å2 (Table 3).
FIG 1 (A) Sensorgrams for the interaction of meropenem substrate with TMB-1, with concentrations of the substrate indicated to the right.
(B) Steady-state plot for meropenem binding to TMB-1. By calculating the steady-state values from the sensorgrams, plotted as a function
of the meropenem concentration and fitted to a single-binding-site model, a KD value of 19 M was determined.
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FIG 2 Structures of L-captopril (A) and inhibitor 2a (B). IC50s of L-captopril (C) and inhibitor 2a (D) were calculated by fitting the data to a dose-response curve
(also see Table 3). Sensorgrams for the interaction of L-captopril (E) and inhibitor 2a (F) with TMB-1, with the concentrations of the inhibitors indicated to the
right. The sensorgrams for binding of inhibitor 2a to TMB-1 were fitted to a 1:1 binding model (red dotted lines). (G) Steady-state plot for binding of L-captopril
to TMB-1. The KD value was determined by calculating the steady-state values from the sensorgrams, plotted as a function of the L-captopril concentration and
fitted to a single-binding-site model.
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The Ramachandran plot of TMB-1 showed values of 98.15% of the residues in the
most favored region, 1.39% of the residues in allowed regions, and 0.46% of the
residues in the disallowed region (Table 4). Here, residue D84 represented a Ramachan-
dran outlier in both TMB-1 chains. D84 has been described to be an outlier in many
MBLs such as VIM-7 (41), VIM-2 (8), IMP-1 (6), and SPM-1 (42) due to the strained
conformation seen under conditions of participation in a conserved network of
H-bonds. The strained conformation of residue D84 has been suggested to play a role
in folding of MBLs (8). D84 in TMB-1 forms contacts with the main and side chains of
T115; the side chain of K121, Y218, and H55; and the main chain of S114. Interactions
of D84 with residues T115, Y218, and K121 are also observed in VIM MBLs (41).
Additional data collection and refinement statistics are given in Tables 3 and 4.
The overall structure of TMB-1 consists of the characteristic /-fold of the MBL
superfamily, with five  helices on the outside toward the solvent and the core formed
by the two -sheets containing 5 and 7 -strands. The active site is located at the edge
TABLE 3 X-ray data collection statistics for the TMB-1 crystal structure
Parameter Result
Diffraction source MX Beamline BL14.1 at BESSY II
Wavelength (Å) 0.918409
Temp (K) 100
Detector Pilatus 6 M
Crystal-detector distance (mm) 426.55
Exposure time per image (s) 0.2
Rotation range per image (°) 0.1
Total rotation range (°) 110
Space group P21212
a, b, c (Å) 44.27, 71.40, 127.20
Resolution (Å) 47.49–1.75 (1.81–1.75)
No. of unique reflections 38,067 (2,395)
Multiplicity 3.8 (2.8)
Completeness (%) 91.9 (59.25)
Rmerge (%) 8.2 (59.3)
Mean I/(I)	 10.8 (1.7)
Overall B-factor from Wilson plot (Å2) 17.09

















Occupancy, Zn1 (chain A/B) 1.0/0.70 (Zn1a) and 0.30 (Zn1b)
Occupancy, Zn2 (chain A/B) 0.95/1.0
Ramachandran plot
Most favored (%) 98.15
Allowed (%) 1.39
Disallowed (%) 0.46
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of the  sandwich surrounded by two loops on each side, including residues 60 to 66
(loop L1) and residues 223 to 240 (loop L3) (Fig. 3A), which are important for the
catalytic activity of the TMB-1 enzyme.
The TMB-1 active site, like those of other B1 MBLs, consists of two zinc ions: Zn1
bound to H116, H118, and H196 and Zn2 bound to D120, C221, and H263 (Fig. 3B). The
zinc binding distances and the angles between the active-site residues are given in
Table S3. Bridging the two zinc ions is a hydroxyl ion; during -lactam hydrolysis, this
hydroxyl ion is likely to perform the nucleophilic attack on the -lactam carbonyl
carbon (43, 44). In chain A, both zinc ions are present in a tetrahedral conformation
coordinated by three binding residues and the hydroxyl ion, but in chain B, Zn1 is
present in a pentahedral conformation coordinated by one additional water molecule,
the hydroxyl ion, and histidine residues 116, 118, and 196. For chain A, the zinc ions
were refined with full occupancy for Zn1 and an occupancy value of 0.95 for Zn2,
resulting in B-factor values of 13.4 Å and 15.3 Å, respectively. In chain B, Zn1 and
the H116 residue were refined with double conformations, with occupancy values
of 0.70 (Zn1a) and 0.30 (Zn1b) (Table 4) and B-factor values of 18.5 Å2 and 15.6 Å2,
respectively. The two H116 conformations for chain B were refined to occupancy
values of 0.63 and 0.37.
FIG 3 The overall structure of TMB-1. (A) The secondary structure of TMB-1 with active-site residues,
including residue E119 (cyan), and the L1 (residues 60 to 66) and L3 (residues 223 to 240) loops (indicated
in blue). (B) The TMB-1 active site, with the three zinc ions indicated in gray, the bridging water molecule
indicated in red, and the two chlorine ions indicated in magenta. The residues binding Zn1 (H116, H118,
and H196) and Zn2 (D120, C221, and H263) and residues V67, W64, W87, E119, R224, S228, and Y233 are
described further in the paper.
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In addition to the two Zn ions, a third Zn3 ion was observed in the TMB-1 chain A
structure, bound to four water molecules and H285 in a surface exposed -helix. Two
Cl ions (Cl1/Cl2) were included in the final TMB-1 structure as interpreted from the
observed electron density. Cl1 is located in between the positively charged R224
residue on the L3 loop and the W64 residue on the L1 loop, while the Cl2 ion is located
between residues P254 and E255 on the surface of the structure on the other. Since the
protein was crystalized from a buffer with 1.0 M NaCl, the presence of chloride ions
seems likely.
Structure-activity relationship analysis of enzymatic behavior of TMB-1. In
order to investigate the TMB-1 structure, a comparison of the active sites of crystal
structures of NDM-1, VIM-2, and GIM-1 was performed through superposition and
structure-activity relationship analysis (Fig. 4).
The results showed that the overall fold was conserved and that the TMB-1 crystal
structure had a root mean square deviation (RMSD) for CA atoms of 1.31 to 1.57 Å
compared to four NDM-1 crystal structures (PDB ID 4RL0, 4HL2, 3SPU, and 3RKJ), 1.40
to 1.58 Å with five VIM-2 crystal structures (PDB ID 5LSC, 5MM9, 4C1D, 1KO2, and 4BZ3),
and 0.62 to 1.44 Å with four GIM-1 structures (PDB ID 2YNW, 2YNT, 2YNV, and 2YNU).
The RMSD for TMB-1 chain A compared to chain B is 0.54 Å, again showing most
differences in the L1 and L3 loops. The two L1 loops of chain A and chain B are facing
each other within the asymmetric unit and are thus involved in the TMB-1 crystal
packing. Residues in the L3 loop are involved in substrate binding, and both the L1 and
L3 loops have been shown to be flexible in, e.g., GIM-1 (18).
The active-site residues of the four compared MBLs are conserved, with some small
movement of the zinc ions and bridging hydroxyl ion; however, the second-shell
residues, such as residue 119 (Fig. 4a), are found in different conformations. The TMB-1
E119 residue is oriented away from the active site; however, the Q119 residue is
positioned toward the active site in NDM-1 complexed with hydrolyzed cefuroxime
(PDB ID 4RL0). This suggests that E119 in TMB-1 may also point toward the active site
upon substrate binding by a simple side chain rotation into a new rotamer. Both TMB-1
and GIM-1 have a glutamic acid residue at position 119, while VIM-2 has the shorter
aspartic residue at this position (Fig. 4c). The orientation of D119 in VIM-2_2b (Fig. 4c)
is shifted slightly upon inhibitor binding, while E119 in NDM-1 points inward upon
cephalosporin substrate binding (Fig. 4b). The surrounding residues are not shifted
significantly between the four superimposed structures, indicating that mutation at the
119 position might not have a large effect on the conformation of the active-site
residues but might have a greater effect on the properties of the second-shell residues.
Further, residue R224 in TMB-1 may contribute to binding of penicillin and cepha-
losporins, similarly to K224 in NDM-1, which is involved in substrate binding (23, 24, 28).
The tyrosine at 224 position in VIM-2 contributes to enhanced binding of positively
charged substrates, such as ceftazidime and cefepime, compared to the arginine and
lysine present at this position in TMB-1, NDM-1, and GIM-1, as shown for the VIM-7
H224Y mutant (36).
TMB-1 and GIM-1 both contain a tyrosine at 233 position, while most MBLs, including
NDM-1 and VIM-2, contain an asparagine (45). The N233 is involved in binding of ceph-
alosporin and penicillin substrates and in binding of inhibitors in NDM-1 (23, 24, 28) and
VIM-2 (30, 46). The substitution of tyrosine to asparagine was investigated in GIM-1 and
showed a reduced level of catalytic efficiency with respect to the tested substrates.
However, in silico energy calculations of levels of ampicillin binding to GIM-1 revealed
that the aromatic ring of the Y233 side chain is close to the C-6 carboxylate of
hydrolyzed ampicillin -lactam and makes a positive energy contribution to the
substrate binding. Taking the data together, other surrounding second-shell residues,
including Y233, might contribute to substrate and inhibitor binding, which would thus
occur in a manner different from that seen with N233. Other studies on second-shell
residues have found an impact on zinc binding affinity (47) and on hydrophobic
interactions interfering with substrate binding (48).
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One of the prominent differences in the L1 loop is the presence of W64 in TMB-1;
the residue is Y64 (GIM-1), F64 (NDM-1), or A64 (VIM-2) in the other compared
structures. The whole L1 loop (and W64 in particular) is found in a closed conformation
in chain A of TMB-1, whereas a slightly more open active site is present in chain B. In
IMP-1, W64 is involved in a T-shaped interaction with a thiophene ring of a mercar-
boxylate inhibitor (6), which can also be achieved in TMB-1. Residue 67 is valine in
TMB-1, NDM-1, and GIM-1, while VIM-2 holds a tyrosine reported to make a -
stacking with the phenyl ring of an inhibitor (8).
In summary, the TMB-1 active site is defined and confined by V61, W64, V67, S228,
and Y233, in addition to R224, thus representing a very hydrophobic binding site
FIG 4 Comparison of the active sites of TMB-1, NDM-1, VIM-2, and GIM-2 crystal structures. (a) Superposition of crystal structures of TMB-1 (green
cartoon and cyan residues), NDM-1 (light pink; PDB ID 4RL0), VIM-2 (yellow; PDB ID 5MM9 [40]), and GIM-1 (orange; PDB ID 2YNW). Residues
conserved in all four structures are black. (b) Superimposed TMB-1 and NDM-1. (c) VIM-2 superimposed on TMB-1. (d) GIM-1 superposition on
GIM-1. The bridging water molecule from TMB-1 is depicted in red. Residues with black labels are common for the compared structures, and
different residues are labeled according to the color of the crystal structures.
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possibly contributing to the overall low level of catalytic efficiency and affecting the
substrate specificity. In particular, the bulky W64 in the L1 loop restricts the size of the
R2 binding site and the flexibility of the loop in TMB.
Modeling of inhibitor 2b in the TMB-1 structure. In order to investigate the
interaction between TMB-1 and inhibitor 2b, the inhibitor was modeled into the active
site through superposition with the previously solved 1.55-Å crystal structure of VIM-
2_2b (40). The IC50 value of inhibitor 2b toward VIM-2 was 0.38 M (40), which is within
the same range as the IC50 value for TMB-1 of 0.62 M.
The observed hydrogen bond from inhibitor 2b to N233 [d(OAEligand. . .NE2N233) 
2.84 Å] in VIM-2 cannot be present in the TMB-1 model due to the presence of Y233.
However, the aromatic ring on the tyrosine may contribute to binding of the inhibitor,
as seen in the free-energy calculation of GIM-1 where Y233 shows -anion interactions
with the C-7 carboxyl on hydrolyzed ampicillin (25). For TMB-1, a  interaction of Y233
with the phosphonate P  O group of 2b might explain the similar IC50 values of VIM-2
and TMB-1. The thiol group in inhibitor 2b can replace the bridging hydroxyl ion
between the two active site zinc ions in TMB-1 as found in the VIM-2_2b structure.
TMB-1 includes S228, which cannot form the cation- interaction mediated by R228 in
VIM-2_2b (PDB ID 5MM9) (Fig. 5). In TMB-1, however, R224 might contribute to the
T-shaped cation- interaction in addition to T-shaped - stacking from both W64 and
H263. The stacking of the phenyl ring of inhibitor 2b is thus tight in binding TMB-1 but
also different from that seen in VIM-2_2b (PDB ID 5MM9). The diethyl groups in the
phosphonate ester of inhibitor 2b may form hydrophobic interactions with residues
W87 and W64 and the carbon atoms in the E119 side chain (Fig. 5B).
The surface and L1 loop of TMB-1 is more closed than that of VIM-2 due to W64
covering the active site. The calculated electrostatic surface potential of TMB-1 and
VIM-2 shows loop L1 to be negatively charged, with E62 (TMB-1) or D62 (VIM-2)
pointing toward the solvent (Fig. 5). But the VIM-2 surface is more negatively charged
overall, resembling the theoretic pI of 4.8 compared to 6.2 for TMB-1 (Table S2).
Conclusion. The Tripoli metallo--lactamase (TMB) enzymes were all found to be
stabilized in buffers with high salt concentrations (1.0 M NaCl). The enzymatic charac-
terization revealed the single S228P mutation as seen in TMB-2 to have shown a slight
reduction in catalytic efficiency and four-times-reduced activity toward ampicillin com-
pared to TMB-1. This agrees with our studies on GIM-1 showing that substitutions at
position 228 affected the enzyme activity (25). In general, the catalytic performance of
TMB-1 was higher than that of TMB-1 E119Q/S/A. Residue E119 was found to affect the
penicillin activity, since all mutants showed catalytic efficiency levels that were 1.1 to 9
times lower. This was the case despite the fact that E119 pointed away from the active
site in the new TMB-1 crystal structure resolved to 1.75 Å; thus, another side chain
rotamer is likely to occur in an enzyme substrate complex.
Among the eight thiol-based inhibitors tested against TMB-1, all showed better
inhibition properties than L-captopril (IC50  47.1 M); inhibitors 2a and 2b showed the
lowest IC50 values (0.66 M and 0.62 M, respectively). As demonstrated using SPR
analysis and TMB-1, inhibitor 2a displayed a binding affinity (KD) value of 1.6 M, which
was 9 times lower than for L-captopril. Modeling of binding of inhibitor 2a in TMB-1
found W64 to contribute to T-shaped - stacking, H263 to T-shaped stacking, and
R224 to cation- interactions with the phenyl ring of the inhibitor. Further, residues
V61, W64, V67, W87, E119 (carbon chain), and Y233 formed hydrophobic interactions
with the ethyl groups on the phosphonate group of the inhibitor. The aromatic Y233
can possibly make an  interaction to the PO group of the inhibitor but not a
hydrogen bond such as from N233 in VIM-2_2b. Taking the data together, the TMB-1
active site is defined and confined by residues V61, W64, V67, S228, and Y233, in
addition to R224 and thus represents a very hydrophobic binding site possibly affecting
substrate specificity and contributing to the overall low catalytic efficiency compared to
other MBLs.
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In a broader perspective, the TMB-1 structure, enzyme characterization, and muta-
tion analyses presented have given further insight into the structure-activity relation-
ship, and the presented 2a and 2b inhibitors are both good starting points for further
inhibitor optimization in the fight against bacteria carrying MBLs.
MATERIALS AND METHODS
blaTMB-1 and blaTMB-2 gene constructs and site-directed mutagenesis of TMB-1. In this study,
synthetic DNA gene constructs of blaTMB-1 and blaTMB-2 in pDEST17 were codon optimized for expression
in Escherichia coli and were purchased from Life Technologies (Thermo Fisher Scientific). The gene
constructs were based on the blaTMB-1 sequence found in Achromobacter xylosoxidans (14) (GenBank
accession number FR771847.1) and the blaTMB-2 sequence from Acinetobacter pittii (16) (GenBank
accession number AB758277.1). Both constructs included an N-terminal hexa-His tag and a tobacco etch
virus (TEV) cleavage site with amino acids ENLYFQG, followed by residues N18 to R245 for TMB-1/TMB-2,
thus removing the prosegment. The gene constructs were transformed into E. coli BL21(DE3) pLysS
(Invitrogen). TMB-1 E119Q/S/A mutants were constructed using a QuikChange site-directed mutagenesis
kit (Agilent Bioscience) and the blaTMB-1 construct as the template. Primers used for the mutations are
listed in Table 5. DpnI was used to digest parental DNA, and the remaining DNA was transformed into
E. coli XL1-Blue cells (Stratagene). Luria-Bertani (LB) agar plates containing 100 g/ml ampicillin (Sigma-
FIG 5 The active site of VIM-2 and of TMB-1 with inhibitor 2b in the active site. (A and B) Calculated
electrostatic surface potential of VIM-2_2b (A) (40) and modeled inhibitor 2b (the new TMB-1; the crystal
structure) (B). The two active site zinc ions are shown as spheres. The red areas represent negatively
charged surface areas, and the blue areas represent positively charged surface areas. The black circles
show the R2 binding site.
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Aldrich) were used for selection of clones. Mutations were confirmed by DNA sequencing (BigDye
Terminator cycle sequencing kit v3.1; Applied Biosystems) with the primers listed in Table 5.
Protein expression and purification. The TMB-1, TMB-2, and TMB-1 E119Q/S/A constructs were
transformed into E. coli BL21(DE3) pLysS (Invitrogen) cells and grown as precultures in LB broth
containing 100 g/ml ampicillin and 34 g/ml chloramphenicol (Sigma-Aldrich) at 37°C overnight. The
precultures were inoculated in Terrific Broth (TB) containing 100 g/ml ampicillin and 34 g/ml
chloramphenicol and grown to log phase (optical density at 600 nm [OD600] of 0.5 to 1.0) at 37°C.
Expression was induced using 1.0 mM (final concentration) isopropyl -D-1-thiogalactopyranoside (IPTG;
Sigma-Aldrich) and incubation at 15°C overnight with constant shaking (180 rpm). The cells were
harvested using centrifugation (8,900  g, 4°C, 40 min), resuspended in buffer A (50 mM HEPES [pH 7.2],
100 M ZnSO4, 1.0 M NaCl), and lysed by sonication. Supernatants were collected by centrifugation
(25,400  g, 40 min, 4°C) and used for purification of TMB-1, TMB-2, and TMB-1 mutants using a 5-ml
His-Trap HP column (GE Healthcare) equilibrated with buffer A. The column was washed with 5% buffer
B (50 mM HEPES [pH 7.2], 1.0 M NaCl, 100 M ZnSO4, 500 mM imidazole) before elution of the enzyme
across a gradient of buffer B (5 to 100%) was performed. Fractions containing TMB enzymes were
detected using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; Bio-Rad). An
in-house-made His-tagged TEV protease (36) was added to the fractions containing TMB-1, TMB-2, or
TMB-1 mutants in a 1:100 ratio of TEV protease/TMB protein to cleave off the His tag. The solutions were
subsequently dialyzed at 4°C overnight in a 10-kDa-molecular-mass-cutoff SnakeSkin dialysis tube
(Pierce) with buffer C (50 mM HEPES [pH 7.2], 300 mM NaCl, 100 M ZnSO4, 2 mM 2-mercaptoethanol).
A second His-Trap purification was performed as described above to remove uncleaved TMB proteins
and the His-tagged TEV protease. Fractions containing cleaved TMB enzymes were pooled and dialyzed
in buffer D (50 mM Tris [pH 8.0]) before a third purification step was performed with an anion exchange
Hitrap Q column and buffer E (50 mM Tris [pH 8.0], 100 M ZnSO4) and eluting with buffer F (50 mM Tris
[pH 8.0], 100 M ZnSO4, 1.0 M NaCl).
The purity of the TMB-containing fractions was estimated using SDS-PAGE, and fractions with purity
of above 95% were pooled and dialyzed against buffer A. The TMB proteins were concentrated by
ultrafiltration using a 10-kDa-molecular-weight-cutoff Ultra centrifugal filter unit (Amicon). The yield of
TMB-1 was 6.9 mg from 1 liter of culture, while the yields of TMB-2, TMB-1 E119Q, TMB-1 E119S, and
TMB-1 E119A were 8.6, 3.7, 2.2, and 1.4 mg, respectively, from 1 liter of culture.
Buffer optimization using thermofluor stability measurement. Thermofluor stability measure-
ments were performed to find stabilizing buffer components prior to crystallization. The fluorescence-
based protein thermal stability was measured using a MJ Mini cycler (Bio-Rad) over a gradient from 15
to 70°C with a heating rate of 1°C min1. The assay had a final volume of 25 l, and the reaction mixture
included 500 nM TMB-1 enzyme, 10 SYPRO Orange solution from a 5,000 stock solution (Sigma-
Aldrich), and different buffer components (given in Table S1 in the supplemental material). The
experiments were performed in duplicate, the results were averaged, and the melting temperature (Tm)
values were determined from the first derivative of the inflection point of the transition. Water was used
as a control, and the Tm values for all of the additives were higher than those calculated for water,
indicated a stabilizing effect.
Determination of kinetic parameters for TMB-1, TMB-2, and TMB-1 E119Q/S/A mutants. The
steady-state enzyme kinetic parameters of TMB-1 and TMB-2 and the TMB-1 variants were determined
by incubation of the enzyme with different -lactam concentrations at 25°C in buffer G (50 mM HEPES
[pH 7.2], 150 mM NaCl, 100 M ZnSO4). The enzyme solutions were diluted to give a final concentration
of 10 nM in buffer H (50 mM HEPES [pH 7.2], 150 mM NaCl, 100 M ZnSO4, 1 mg/ml bovine serum
albumin [BSA]). BSA was added to prevent loss of enzyme activity due to a low protein concentration and
to prevent protein unfolding (50, 51). The substrate concentrations ranged from 0.12 M to 2,000 M.
All reactions were performed in UV-transparent 96-well plates or, for the penicillins, in half-well plates
(Corning) with a total reaction volume of 100 l. The initial rate of -lactam hydrolysis was measured
using a SpectraMax M2e spectrophotometer (Molecular Devices) and fitted to the Michaelis-Menten
equation (equation 1) using GraphPad Prism software (GraphPad, v5.0) to obtain the steady-state kinetic





where v is the initial velocity measured, Km is the Michaelis constant, kcat is the turnover number, and [S]
and [E] are substrate and enzyme concentrations, respectively. Initial rates were measured in triplicate,
and the results were averaged to determine Km and kcat values calculated from the Vmax values also using
the enzyme concentrations.
TABLE 5 Primers used for TMB-1 site-directed mutagenesis and sequencinga
Primer name Forward primer sequence (5=–3=) Tm (°C) Reverse primer sequence (5=–3=) Tm (°C)
TMB-1 E119Q ACCCATAGCCATCAAGATAAAACCGCA 74.7 TGCGGTTTTATCTTGATGGCTATGGGT 74.7
TMB-1 E119S ACCCATAGCCATTCAGATAAAACCGCA 74.7 TGCGGTTTTATCTGAATGGCTATGGGT 74.7
TMB-1 E119A ACCCATAGCCATGCAGATAAAACCGCA 76.2 TGCGGTTTTATCTGCATGGCTATGGGT 76.2
M13 GTAAAACGACGGCCAGT 47.1 GGAAACAGCTATGACCATG 48.9
aMutated nucleotides are underlined. Melting temperatures were calculated at http://www.biophp.org/minitools/melting_temperature/demo.php.
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The indicated wavelengths and extinction coefficients were used in this study for the following
antibiotics: meropenem (Δ300  6,500 M1 cm1, 0.5 to 1,000 M), imipenem (Δ300  9,000 M1
cm1, 0.5 to 1,000 M), doripenem (Δ300  7,540 M1 cm1, 0.5 to 1,000 M), cefotaxime (Δ260 
7,500 M1 cm1, 0.2 to 500 M), ceftazidime (Δ260  9,000 M1 cm1, 0.1 to 250 M), cefepime
(Δ260  10,000 M1 cm1, 0.2 to 500 M), cefoxitin (Δ260  7,700 M1 cm1, 0.5 to 1,000 M),
benzylpenicillin (Δ235  775 M1 cm1, 1,000 to 2,000 M), ampicillin (Δ235  820 M1 cm1, 1,000
to 2,000 M), piperacillin (Δ235  820 M1 cm1, 0.06 to 62.5 M), and nitrocefin (Δ282  17,400 M1
cm1, 0.5 to 250 M).
Determination of half-maximal (50%) inhibitory concentration (IC50) values for thiol-based
inhibitors toward TMB-1. In our recent study, we described the organic synthesis details and inhibitor
properties of many new thiol-based inhibitors against VIM-2, NDM-1, and GIM-1 (40). Here, the half-
maximal (50%) inhibitory concentration (IC50) values were determined for L-captopril and eight of the
new thiol-based inhibitors (40) with TMB-1 at 25°C in 96-well plates using a SpectraMax M2e spectro-
photometer. The inhibitors were dissolved in dimethyl sulfoxide (DMSO) and were further diluted in
buffer G, resulting in a final DMSO proportion of a maximum of 2.5% in the assay. The TMB-1 enzyme
was diluted to a final concentration of 1 nM in buffer H. Nitrocefin was used at a final concentration of
50 M as a reporter substrate. TMB-1 and the inhibitors were incubated for 5 min before nitrocefin was
added and the OD482 was measured every 30 s for 30 min. The measurements were performed in
duplicate, in an assay with a 2-fold dilution series of the inhibitors starting at 2.5 mM and 250 M (for
inhibitors 2a and 2b). The breakdown of nitrocefin was monitored at 482 nm, measuring the initial
velocity for each inhibitor concentration. The values were normalized to those determined for a positive
control with no inhibitor added to the measurements. The IC50 values were calculated by plotting the
initial velocities against the inhibitor concentration and fitting the data to a dose-response curve using
a constant top plateau value (100%), a constant bottom plateau value (0%), and a constant Hill slope
value of 1 in the GraphPad Prism 5 software (GraphPad v5.0).
Binding studies using surface plasmon resonance (SPR). Binding of the inhibitors was studied
using surface plasmon resonance (SPR)-based assays. SPR experiments were performed at 25°C using a
Biacore T200 system (GE Healthcare), and the data were analyzed with Biacore T200 evaluation software
2.0 (GE Healthcare). All binding studies were performed in running buffer I (consisting of 50 mM HEPES
[pH 7.2], 150 mM NaCl, 100 M ZnSO4, 0.005% surfactant P-20 [GE Healthcare], and 2.5% DMSO).
Standard amine coupling and streptavidin-biotin capturing were used to immobilize TMB-1 to a CM5
chip (GE Healthcare). For the standard amine coupling, TMB-1 was diluted directly in buffer J (10 mM
sodium acetate [pH 5.0], 100 M ZnSO4) to a concentration of 200 g/ml and injected for 420 s over an
activated surface at a flow rate of 10 l/min. For the streptavidin-biotin capturing, TMB-1 was biotinyl-
ated in a mixture of a 1:1 molar ratio with biotinamidohexanoic acid N-hydroxysuccinimide ester
(Sigma-Aldrich) in a 0.1 M phosphate buffer (pH 7.2) and incubated at room temperature for 30 min. An
Amicon Ultra centrifugal filter (Merck Millipore Ltd.) was used with a 10-kDa-molecular-mass cutoff to
remove the unreacted biotinamidohexanoic acid N-hydroxysuccinimide ester. Streptavidin was dissolved
in 10 mM sodium acetate (pH 4.8) to a concentration of 300 g/ml and immobilized to the sensor surface
using standard amine coupling and an injection time of 1,200 s. Biotinylated TMB-1 was injected with a
5 l/min flow rate for 240 s over the surface with immobilized streptavidin. A surface without immobi-
lized TMB-1 was used for reference subtraction.
To determine the binding affinity (KD) of meropenem, L-captopril {N-[(S)-3-mercapto-2-methylpro-
pionyl]-L-proline; Sigma-Aldrich}, and inhibitor 2a, the compounds were dissolved in running buffer I and
injected in a 2-fold dilution concentration series ranging from 400 to 3 M meropenem and from 250
to 2 M L-captopril, while the concentration series for inhibitor 2a ranged from 6 to 0.05 M. The
association from the inhibitor was detected for 180 s or 120 s and the dissociation for 300 s. Solvent
correction was used to correct bulk effects, and running buffer I was used for blank injections. All
sensorgrams were subjected to reference and blank subtraction. In order to calculate the binding affinity
(KD) for meropenem and L-captopril, the steady-state values were calculated from the sensorgram and
plotted as a function of concentration and fitted to a 1:1 interaction model. For inhibitor 2a, the KD was
determined by fitting the sensorgram data to a 1:1 binding model. KD values were determined by using
Biacore T200 evaluation software 2.0 (GE Healthcare).
TMB-1 and TMB-2 crystallization experiments. Crystallization trials were set up for both TMB-1
(10.4 mg/ml) and TMB-2 (11.2 mg/ml) with the sitting-drop method using a Phoenix DT crystallization
robot (Rigaku) and drops of 500 nl protein and 500 nl reservoir solution in 96-well MRC plates (Molecular
Dimensions) with a 60-l reservoir volume. Crystals were achieved only for TMB-1. High-quality diffrac-
tion crystals of TMB-1 were obtained after 4 weeks of incubation at room temperature. The TMB-1 crystals
were grown in 0.10 M HEPES (pH 8.0)– 4.75% glycerol–32% polyethylene glycol (PEG) monomethyl ether
(MME) 2000. All crystals were flash frozen in liquid nitrogen. Crystallization trials of TMB-1 were
performed using low-salt buffer (
200 mM NaCl) and high-salt buffer A (1.0 M NaCl, 50 mM HEPES [pH
7.2], 100 M ZnSO4).
Data collection and structure determination, refinement, and analysis. The X-ray data collection
was performed at beamline BL14.1 at Berliner Elektronenspeicherring-Gesellschaft für Synchrotronstrahl-
ung mbH (BESSY), Berlin, Germany, and the data were integrated, scaled, and truncated in XDS, XSCALE
(52), and AIMLESS (53).
A homology model was made using DIM-1 (PDB ID 4ZEJ) and the TMB-1 sequence in the program
SWISS-MODEL (54), and this model was used to solve the TMB-1 structure by molecular replacement in
PHASER crystallographic software (55). The structure was refined in Phenix software (56) with manual
rebuilding in the graphical program WinCoot (57). All structural figures were made using PyMol (58).
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The theoretical values for pI and the grand average of hydropathicity index (GRAVY) were calculated
using the Expasy Web server (http://web.expasy.org/protparam/). The residues included in the gene
constructs were TMB-1 G plus N18-R245, NDM-1 G plus G29-R294 (59), VIM-2 G plus V27-E245 (27), and
GIM-1 A plus G19-D250 (25), where the first residue remains after TEV cleavage. GRAVY values are calculated
by adding the hydropathy value for each residue and dividing by the sequence length (60) where, e.g.,
isoleucine has a value of 4.5 (most hydrophobic) and arginine has a value of 4.5 (most polar).
Accession number(s). Coordinate and structure factor files for TMB-1 (PDB ID 5MMD) have been
deposited and released in the Protein Data Bank (PDB).
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